Literature DB >> 15343539

Antibiotic-loaded articulating cement spacer in the 2-stage exchange of infected total knee arthroplasty.

Sridhar M Durbhakula1, John Czajka, Marc D Fuchs, Richard L Uhl.   

Abstract

An antibiotic-loaded articulating cement spacer (ALACS) was used in the 2-stage exchange of infected total knee arthroplasty. Specially designed molds produced articulating femoral and tibial spacer components. Twenty-four consecutive patients were followed for an average of 33 months (range, 28-51 months). Two patients (8%) had a persistent infection after the first stage. Twenty-two patients (92%) underwent a successful 2-stage exchange. Minimal soft-tissue contracture and minimal bone loss were encountered during reimplantation. None of these patients developed a recurrent or persistent infection. The average postoperative knee flexion was 104 degrees (range, 89 degrees-122 degrees). The average Hospital for Special Surgery score was 82 (range, 63-96). The ALACS spacer preserved knee function between stages, resulting in effective treatment of infection, facilitation of reimplantation, and improved patient satisfaction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15343539     DOI: 10.1016/j.arth.2004.02.036

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  38 in total

Review 1.  Two-stage revision of septic knee prosthesis with articulating knee spacers yields better infection eradication rate than one-stage or two-stage revision with static spacers.

Authors:  C L Romanò; L Gala; N Logoluso; D Romanò; L Drago
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-01-21       Impact factor: 4.342

2.  Intraoperative molds to create an articulating spacer for the infected knee arthroplasty.

Authors:  Geoffrey S Van Thiel; Keith R Berend; Gregg R Klein; Alexander C Gordon; Adolph V Lombardi; Craig J Della Valle
Journal:  Clin Orthop Relat Res       Date:  2011-04       Impact factor: 4.176

3.  The use of spacers (static and mobile) in infection knee arthroplasty.

Authors:  Luca Mazzucchelli; Federica Rosso; Antongiulio Marmotti; Davide Edoardo Bonasia; Matteo Bruzzone; Roberto Rossi
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

Review 4.  [Periprosthetic knee infection. One-stage exchange].

Authors:  C Friesecke; J Wodtke
Journal:  Orthopade       Date:  2006-09       Impact factor: 1.087

5.  Assessing the gold standard: a review of 253 two-stage revisions for infected TKA.

Authors:  Tahir Mahmud; Matthew C Lyons; Douglas D Naudie; Steven J Macdonald; Richard W McCalden
Journal:  Clin Orthop Relat Res       Date:  2012-10       Impact factor: 4.176

6.  Does knee revision after an articulated spacer implant provide normal gait restoration?

Authors:  Nicola Logoluso; Alice Nardo; Federica Anasetti; Sara Scarponi; Carlo Luca Romanò
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-10-19       Impact factor: 4.342

7.  Unsatisfactory outcome of arthrodesis performed after septic failure of revision total knee arthroplasty.

Authors:  Eric Röhner; Christoph Windisch; Katy Nuetzmann; Max Rau; Michael Arnhold; Georg Matziolis
Journal:  J Bone Joint Surg Am       Date:  2015-02-18       Impact factor: 5.284

8.  Two-stage treatment of infected total knee arthroplasty: two to thirteen year experience using an articulating preformed spacer.

Authors:  Claudio Carlo Castelli; Valerio Gotti; Roberto Ferrari
Journal:  Int Orthop       Date:  2014-01-26       Impact factor: 3.075

9.  Infection recurrence factors in one- and two-stage total knee prosthesis exchanges.

Authors:  P Massin; T Delory; L Lhotellier; G Pasquier; O Roche; A Cazenave; C Estellat; J Y Jenny
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-11-26       Impact factor: 4.342

Review 10.  Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach.

Authors:  Esa Jämsen; Ioannis Stogiannidis; Antti Malmivaara; Jorma Pajamäki; Timo Puolakka; Yrjö T Konttinen
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.